Market Access 2020: Understanding US Payer Expectations
How Much Longer For Biopharma’s Habitual Hamlet Fixation: To Risk Or Not To Risk?
Executive Summary
Big pharma is facing a difficult US competitive landscape as its traditional customers realign to build their own redoubts of size, scale and reach.
You may also be interested in...
Bayer US Pharmaceuticals’ Sebastian Guth: Designs On A New Decade
Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.
Gates MRI CEO Penny Heaton Speaks …
Insights from Gates Medical Research Institute CEO Dr. Penny Heaton.
Gates Foundation Plots A Fresh Metric For Market Access: Lives Saved
In Vivo visits Gates Medical Research Institute CEO Dr. Penny Heaton to review its first pipeline of drugs and vaccines to attack four of the world’s biggest killers: TB, malaria, enteric diseases and other conditions affecting maternal, newborn and child health.
Need a specific report? 1000+ reports available
Buy Reports